The Tissue Bank and Biomarkers Core (TBBC) is the central repository of specimens necessary for the execution of the studies of the Colorado SPORE In Lung Cancer program. Furthermore, as an extensive resource for lung cancer related specimens, the TBBC also provides specimens to extramural investigators when there are adequate materials to accommodate these requests beyond the needs of the internal projects. The three primary goals of the TBBC are to procure, characterize and process, and distribute specimens. The provision of these services takes advantage of a close working relationship with the existing facilities, infrastructure, and personnel for biobanking and histology operations of the University of Colorado Cancer Center Tissue Biobanking and Processing Shared Resource. Two general banks are maintained: a tumor bank and a premalignant bank. Specimens for both of these banks are collected as archival tissue or, in collaboration with the Clinical Trials Core, SPORE trial associated specimens and are obtained under IRB approved protocols. In addition to tissue, ancillary specimens including blood, sputa, urine and special bronchoscopic specimens are collected. The TBBC, in collaboration with the Biostatistics and Bioinformatics core of the SPORE, also collects correlative clinical and biologic information that can be included in specimen distributions. The TBBC provides histologic and cytologic interpretation, prepares RNA, DNA and protein samples, creates TMAs and provides molecular analysis on selected specimens required by the SPORE projects. This includes histologic review and classification by up-to-date published WHO classification systems for malignant and pre-malignant lesions of the lung by the pathologist members of the core. The core designs its activities to meet the needs of each of the SPORE projects as outlined In the proposal. In order to meet the tissue needs and achieve the goals of the projects, the TBBC collects and processes tissues in a specific manner as determined via collaboration with project investigators. The TBBC also collaborates in the performance of project related studies in which expertise of TBBC personnel can benefit study design, data generation, and data analysis.

Public Health Relevance

The Tissue Biobanking and Biomarkers Core (TBBC) is essential to the success of the Colorado SPORE In Lung Cancer program. The TBBC is a central service that obtains tissues and information from patients with lung cancer or at high-risk for lung cancer. The collected tissue and Information is stored and processed so that researchers have the best possible materials and Information for their projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-23
Application #
9518422
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
23
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Ravichandran, Kameswaran; Holditch, Sara; Brown, Carolyn N et al. (2018) IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol 314:F356-F366
Hilberg, Frank; Tontsch-Grunt, Ulrike; Baum, Anke et al. (2018) Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther 364:494-503
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
DeHart, David N; Fang, Diana; Heslop, Kareem et al. (2018) Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol 148:155-162
Patil, Tejas; Smith, Derek E; Bunn, Paul A et al. (2018) The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol 13:1717-1726
Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507
Helfrich, Barbara A; Gao, Dexiang; Bunn Jr, Paul A (2018) Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer 118:148-154
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 435 publications